Literature DB >> 26331377

Long-term survivors after pancreatectomy for cancer: the TNM classification is outdated.

Lionel Jouffret1, Olivier Turrini1, Jacques Ewald1, Vincent Moutardier2, Juan Lucio Iovanna3, Jean-Robert Delpero1.   

Abstract

BACKGROUND: According to knowledge, patients with resectable pancreatic adenocarcinoma (PA) should receive adjuvant gemcitabine-based chemotherapy. Thus, the tumour node metastasis (TNM) classification is not used to determine post-operative treatment but rather only to establish patient prognosis. However, the TNM classification does not include strong factors influencing survival, such as perineural invasion or margin status. This study compared the survival of patients with very similar tumours.
METHODS: From 1997 to 2007, 118 patients underwent pancreatectomy for PA. Twenty-six patients (22%) had long-term survival (>5 years; LTS group). According to the major prognostic factors of PA, we matched (1:1) patients in the LTS group with patients who did not have long-term survival (<5 years; control group).
RESULTS: Surprisingly, we did not have any difficulty identifying patients to include in the control group. Consequently, no differences were noted between patients of the LTS group when compared with patients of the control group according to major prognostic factors and the TNM classification. Three patients (12%) in the LTS group had positive margin status, and two patients (8%) had positive lymph node status. Unsurprisingly, the median survival for the control group versus the LTS group was 16 months versus not reached (P < 0.01).
CONCLUSION: The lack of difficulty in matching the two groups confirmed that patients of the LTS group did not have an exclusive tumour pattern. TNM classification is outdated because it did not influence adjuvant therapies and did not include two crucial factors: tumour biology and tumour response to chemo/radio therapies.
© 2015 Royal Australasian College of Surgeons.

Entities:  

Keywords:  TNM classification; adenocarcinoma; pancreatectomy; survival

Mesh:

Year:  2015        PMID: 26331377     DOI: 10.1111/ans.13277

Source DB:  PubMed          Journal:  ANZ J Surg        ISSN: 1445-1433            Impact factor:   1.872


  5 in total

1.  Gene Expression Profiling and PRAME Status Versus Tumor-Node-Metastasis Staging for Prognostication in Uveal Melanoma.

Authors:  Louis Cai; Manuel Paez-Escamilla; Scott D Walter; Bercin Tarlan; Christina L Decatur; Barbara M Perez; J William Harbour
Journal:  Am J Ophthalmol       Date:  2018-08-06       Impact factor: 5.258

2.  Prognostic Significance of New AJCC Tumor Stage in Patients With Pancreatic Ductal Adenocarcinoma Treated With Neoadjuvant Therapy.

Authors:  Deyali Chatterjee; Matthew H Katz; Wai Chin Foo; Manonmani Sundar; Hua Wang; Gauri R Varadhachary; Robert A Wolff; Jeffrey E Lee; Anirban Maitra; Jason B Fleming; Asif Rashid; Huamin Wang
Journal:  Am J Surg Pathol       Date:  2017-08       Impact factor: 6.298

3.  Development and validation of a prognostic model to predict the prognosis of patients who underwent chemotherapy and resection of pancreatic adenocarcinoma: a large international population-based cohort study.

Authors:  Lei Huang; Yesilda Balavarca; Lydia van der Geest; Valery Lemmens; Liesbet Van Eycken; Harlinde De Schutter; Tom B Johannesen; Vesna Zadnik; Maja Primic-Žakelj; Margit Mägi; Robert Grützmann; Marc G Besselink; Petra Schrotz-King; Hermann Brenner; Lina Jansen
Journal:  BMC Med       Date:  2019-03-25       Impact factor: 8.775

4.  Development and validation of novel nomograms for predicting the survival of patients after surgical resection of pancreatic ductal adenocarcinoma.

Authors:  Ge Li; Jiang-Zhi Chen; Shi Chen; Sheng-Zhe Lin; Wei Pan; Ze-Wu Meng; Xin-Ran Cai; Yan-Ling Chen
Journal:  Cancer Med       Date:  2020-03-17       Impact factor: 4.452

5.  Shikonin regulates invasion and autophagy of cultured colon cancer cells by inhibiting yes-associated protein.

Authors:  Jing Zhu; Lei Zhao; Bin Luo; Wang Sheng
Journal:  Oncol Lett       Date:  2019-10-11       Impact factor: 2.967

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.